These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
425 related articles for article (PubMed ID: 9001162)
1. Bisphosphonate therapy. Licata AA Am J Med Sci; 1997 Jan; 313(1):17-22. PubMed ID: 9001162 [TBL] [Abstract][Full Text] [Related]
2. Treatment of osteoporosis with bisphosphonates. Watts NB Rheum Dis Clin North Am; 2001 Feb; 27(1):197-214. PubMed ID: 11285996 [TBL] [Abstract][Full Text] [Related]
3. Bisphosphonates: preclinical aspects and use in osteoporosis. Fleisch HA Ann Med; 1997 Feb; 29(1):55-62. PubMed ID: 9073324 [TBL] [Abstract][Full Text] [Related]
4. Bisphosphonates for osteoporosis. Drug Ther Bull; 2001 Sep; 39(9):68-72. PubMed ID: 11586803 [TBL] [Abstract][Full Text] [Related]
6. Oral bisphosphonates: A review of clinical use in patients with bone metastases. Major PP; Lipton A; Berenson J; Hortobagyi G Cancer; 2000 Jan; 88(1):6-14. PubMed ID: 10618600 [TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of alendronate and risedronate for postmenopausal osteoporosis. Iwamoto J; Takeda T; Sato Y Curr Med Res Opin; 2006 May; 22(5):919-28. PubMed ID: 16709313 [TBL] [Abstract][Full Text] [Related]
9. Clinical pharmacology of potent new bisphosphonates for postmenopausal osteoporosis. Chapurlat RD Treat Endocrinol; 2005; 4(2):115-25. PubMed ID: 15783248 [TBL] [Abstract][Full Text] [Related]
10. Aging bone and osteoporosis: strategies for preventing fractures in the elderly. Ettinger MP Arch Intern Med; 2003 Oct; 163(18):2237-46. PubMed ID: 14557222 [TBL] [Abstract][Full Text] [Related]
11. Morphological assessment of basic multicellular unit resorption parameters in dogs shows additional mechanisms of bisphosphonate effects on bone. Allen MR; Erickson AM; Wang X; Burr DB; Martin RB; Hazelwood SJ Calcif Tissue Int; 2010 Jan; 86(1):67-71. PubMed ID: 19953232 [TBL] [Abstract][Full Text] [Related]
12. Optimizing administration of bisphosphonates in women with postmenopausal osteoporosis. Rackoff PJ; Sebba A Treat Endocrinol; 2005; 4(4):245-51. PubMed ID: 16053341 [TBL] [Abstract][Full Text] [Related]
13. Current bone mineral density data on bisphosphonates in postmenopausal osteoporosis. McClung MR Bone; 1996 Nov; 19(5 Suppl):195S-198S. PubMed ID: 8922662 [TBL] [Abstract][Full Text] [Related]
14. Role of alendronate and risedronate in preventing and treating osteoporosis. Peters ML; Leonard M; Licata AA Cleve Clin J Med; 2001 Nov; 68(11):945-51. PubMed ID: 11718433 [TBL] [Abstract][Full Text] [Related]
15. Antiresorption therapy and reduction in fracture susceptibility in the osteoporotic elderly patient: open study. Muscoso E; Puglisi N; Mamazza C; Lo Giudice F; Testai M; Abbate S; Santangelo A; Panebianco P; Maugeri D Eur Rev Med Pharmacol Sci; 2004; 8(2):97-102. PubMed ID: 15267123 [TBL] [Abstract][Full Text] [Related]
16. An update on bisphosphonates. Cohen SB Curr Rheumatol Rep; 2004 Feb; 6(1):59-65. PubMed ID: 14713403 [TBL] [Abstract][Full Text] [Related]
17. Drug insight: Bisphosphonates for postmenopausal osteoporosis. Chapurlat RD; Delmas PD Nat Clin Pract Endocrinol Metab; 2006 Apr; 2(4):211-9; quiz following 238. PubMed ID: 16932286 [TBL] [Abstract][Full Text] [Related]
18. Clinical trials with bisphosphonates. Lombardi A; Santora AC Ann Ital Med Int; 1992; 7(3 Suppl):158S-165S. PubMed ID: 1297394 [TBL] [Abstract][Full Text] [Related]
19. Fracture risk in women with osteoporosis initiated on gastro-resistant risedronate versus immediate release risedronate or alendronate: a claims data analysis in the USA. Eisman JA; Cortet B; Boolell M; Ionescu-Ittu R; Vekeman F; Heroux J; Thomasius F Osteoporos Int; 2023 May; 34(5):977-991. PubMed ID: 36872338 [TBL] [Abstract][Full Text] [Related]
20. Fracture protection in osteoporosis with risedronate. Boonen S; Vanderschueren D Hosp Med; 2004 Sep; 65(9):535-40. PubMed ID: 15449490 [No Abstract] [Full Text] [Related] [Next] [New Search]